Evaluation of HER-2/neu oncogene status in breast tumors on tissue microarrays

Human Pathology

Volumn 34, Issue 4, 2003, Pages 362-368

  Zhang, Daohai ^b   Salto Tellez, Manuel ^b   Do, Elaine ^b   Putti, Thomas Choudary ^b   Koay, Evelyn S C ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NONE

Author keywords

Breast tumors; Fluorescence in situ hybridization; HER 2 neu; Immunohistochemistry; Tissue microarrays

Indexed keywords

ESTROGEN RECEPTOR; ONCOPROTEIN; PROGESTERONE RECEPTOR;

ARTICLE; BREAST TUMOR; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA MICROARRAY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENETIC PROCEDURES; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE NEU; STATISTICAL SIGNIFICANCE; TUMOR CLASSIFICATION;

EID: 0038077396     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1053/hupa.2003.60     Document Type: Article

References (35)

1. Popescu NC, King CR, Kraus MH: Localization of human erbB2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. Genomics 4:362-364, 1989
2. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989
3. Ross JS, Fletcher JA: HER-2/neu (c-erbB2) gene and protein in breast cancer. Am J Clin Pathol 112:S53-S67, 1999
4. Pauletti G, Godolphin W, Press MF, et al: Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 13:63-72, 1996
5. Kallioniemi OP, Kallioniemi A, Kurisu W, et al: ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci U S A 89:5321-5325, 1992
6. Tsuda H, Akiyama F, Terasaki H, et al: Detection of HER-2/neu DNA amplification in primary breast carcinoma: Interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression. Cancer 92:2965-2974, 2001
7. Earp HS, Dawson TL, Li X, et al: Heterodimerization and functional interaction between EGF receptor family members: A new signaling paradigm with implications for breast cancer research. Breast Cancer Res Treat 35:115-132, 1995
8. Fukushi Y, Sato S, Yokoyama Y, et al: Detection of numerical aberration in chromosome 17 and c-erbB2 gene amplification in epithelial ovarian cancer using recently established dual color FISH. Eur J Gynaecol Oncol 22:23-25, 2001
9. Khan AJ, King BL, Smith BD, et al: Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma. Clin Cancer Res 8:540-548, 2002
10. Takehana T, Kunitomo K, Kono K, et al: Status of c-erbB2 in gastric adenocarcinoma: A comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immunosorbent assay. Int J Cancer 98:833-837, 2002
11. Hirsch FR, Varella-Garcia M, Franklin WA, et al: Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. Br J Cancer 86:1449-1456, 2002
12. Potti A, Willardson J, Forseen C, et al: Predictive role of HER-2/neu overexpression and clinical features at initial presentation in patients with extensive stage small cell lung carcinoma. Lung Cancer 36:257-261, 2002
13. Cobleigh MA, Vogel CL, Tripathy D, et al: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648, 1999
14. Kallioniemi OP, Holli K, Visakorpi T, et al: Association of c-erbB2 protein overexpression with high rate of cell proliferation, increased risk for visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 49:650-655, 1991
15. Lehr HA, Jacobs TW, Yaziji H, et al: Quantitative evaluation of HER-2/neu status in breast cancer by fluorescence in situ hybridization and by immunohistochemistry with image analysis. Am J Clin Pathol 115:814-822, 2001
16. Wang S, Saboorian H, Frenkel EP, et al: Aneusomy 17 in breast cancer: Its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status. Mod Pathol 15:137-145, 2002
17. Jimenez RE, Wallis T, Tabasczka P, et al: Determination of Her-2/neu status in breast carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization. Mod Pathol 13:37-45, 2000
18. Kobayashi M, Ooi A, Oda Y, et al: Protein overexpression and gene amplification of c-erbB2 in breast carcinomas: A comparative study of immunohistochemistry and fluorescence in situ hybridization of formalin-fixed, paraffin-embedded tissues. HUM PATHOL 33:21-28, 2002
19. Ridolfi RL, Jamehdor MR, Arber JM: HER-2/neu testing in breast carcinoma: A combined immunohistochemical and fluorescence in situ hybridization approach. Mod Pathol 13:866-873, 2000
20. Tubbs RR, Pettay JD, Roche PC, et al: Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: Apparent immunohistochemical false-positives do not get the message. J Clin Oncol 19:2714-2721, 2001
21. Press MF, Bernstein L, Thomas PA, et al: HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas. J Clin Oncol 15:2894-2904, 1997
22. Rosenthal SI, Depowski PL, Sheehan CE, et al: Comparison of HER-2/neu oncogene amplification detected by fluorescence in situ hybridization in lobular and ductal breast cancer. Appl Immunohistochem Mol Morphol 10:40-46, 2002
23. Depowski PL, Brien TP, Sheehan CE, et al: Prognostic significance of p34cdc2 cyclin-dependent kinase and MIB1 overexpression, and HER-2/neu gene amplification detected by fluorescence in situ hybridization in breast cancer. Am J Clin Pathol 112:459-469, 1999
24. Cianciulli AM, Botti C, Coletta AM, et al: Contribution of fluorescence in situ hybridization to immunohistochemistry for the evaluation of HER-2 in breast cancer. Cancer Genet Cytogenet 133: 66-71, 2002
25. Kononen J, Bubendorf L, Kallioniemi A, et al: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4:844-847, 1998
26. Zhang DH, Salto-Tellez M, Putti TC, et al: Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer. Mod Pathol 16:79-85, 2003
27. Jacobs TW, Gown AM, Yaziji H, et al: Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol 17: 1974-1982, 1999
28. Xu R, Perle MA, Inghirami G, et al: Amplification of HER-2/neu gene in HER-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material. Mod Pathol 15:116-124, 2002
29. Pauletti G, Dandekar S, Rong H, et al: Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 18:3651-3664, 2000
30. Wang S, Saboorian MH, Frenkel E, et al: Laboratory assessment of the status of HER-2/neu protein and oncogene on breast cancer specimens: Comparison of immunohistochemistry assay with fluorescence in situ hybridization assays. J Clin Pathol 53:374-381, 2000
31. Ratcliffe N, Wells W, Wheeler K, et al: The combination of in situ hybridization and immunohistochemical analysis: An evaluation of HER-2/neu expression in paraffin-embedded breast carcinomas and adjacent normal-appearing breast epithelium. Mod Pathol 10: 1247-1252, 1997
32. Ross JS, Sheehan C, Hayner-Buchan AM, et al: HER-2/neugene amplification status in prostate cancer by fluorescence in situ hybridization. HUM PATHOL 28:827-833, 1997
33. Allred DC, Clark GM, Molina R, et al: Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. HUM PATHOL 23:974-979, 1992
34. Couturier J, Vincent-Salomon A, Nicolas A, et al: Strong correlation between results of fluorescence in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/ neu) gene status in breast carcinoma. Mod Pathol 13:1238-1243, 2000
35. Hoang MP, Sahin AA, Ordonez NG, et al: HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. Am J Clin Pathol 113:852-859, 2000